Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1735-1743

  Allegra, Carmen J ^a   Parr, Allyson L ^a   Wold, Lester E ^a   Mahoney, Michelle R ^a   Sargent, Daniel J ^a   Johnston, Patrick ^a   Klein, Pam ^a   Behan, Katie ^a   O'Connell, Michael J ^a   Levitt, Ralph ^a   Kugler, John W ^a   Tirona, Maria Tria ^a   Goldberg, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; LEVAMISOLE; PROTEIN P53; RECOMBINANT GAMMA INTERFERON; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLON CANCER; COLON RESECTION; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036534002     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.080     Document Type: Article

References (55)

1. Colorectal cancer biology: Clinical implications
2. Cancer: p53, guardian of the genome
3. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents
4. Wild-type p53 protein potentates cytotoxicity of therapeutic agents in human colon cancer cells
5. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
6. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
7. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
8. A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas
9. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
10. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas
11. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer
12. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma
13. p22/WAF1 expression in human colorectal carcinoma: Association with p53, transcription factor AP-2 and prognosis
14. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis
15. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance
16. p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients
17. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma
18. p53 expression in colorectal cancer: Relation to tumor type - DNA ploidy pattern and short-term survival
19. Clinico-pathological correlation and prognostic significance of nuclear p53 protein in colorectal cancer: Colorectal Cancer Study Group of the University and Health Care District of Modena
20. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer
21. Prognostic value of p53 genetic changes in colorectal cancer
22. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma
23. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
24. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
25. p53 alterations are associated with improved prognosis in distal colonic carcinomas
26. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma
27. S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: Implications for adjuvant chemotherapy
28. Comparison of double and single parameters in DNA analysis for staging and as a prognostic indicator in patients with colon and rectal carcinoma
29. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas
30. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry
31. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
32. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations
33. LY231514, a pyrrolo[2,3 d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
34. Antifolates: The next millennium
35. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy
36. The production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissues
37. Thymidylate synthase gene and protein expression correlate and are associated with a response to 5-fluorouracil in human colorectal and gastric tumors
38. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil
39. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion
40. Levamisole and fluorouracil for adjuvant therapy of resected colon cancer
41. Controlled clinical trial of interferon gamma as postoperative surgical adjuvant therapy for colon cancer
42. Effective surgical adjuvant therapy for high-risk rectal carcinoma
43. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site
44. Cancer statistics, 2000
45. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
46. Proportional hazards test and diagnostics based on weighted residuals
47. Therapy for early stage colorectal cancer
48. The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer
49. Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival
50. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
51. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors
52. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
53. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
54. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance
55. Prognostic value of thymidylate synthase (TS), Ki-67 and p53 in patients (pts) with Dukes' B & C colon cancer